Literature DB >> 23427256

Blocking properdin, the alternative pathway, and anaphylatoxin receptors ameliorates renal ischemia-reperfusion injury in decay-accelerating factor and CD59 double-knockout mice.

Takashi Miwa1, Sayaka Sato, Damodar Gullipalli, Masaomi Nangaku, Wen-Chao Song.   

Abstract

Complement is implicated in the pathogenesis of ischemia-reperfusion injury (IRI). The activation pathway(s) and effector(s) of complement in IRI may be organ specific and remain to be fully characterized. We previously developed a renal IRI model in decay-accelerating factor (DAF) and CD59 double-knockout (DAF(-/-)CD59(-/-)) mice. In this study, we used this model to dissect the pathway(s) by which complement is activated in renal IRI and to evaluate whether C3aR- or C5aR-mediated inflammation or the membrane attack complex was pathogenic. We crossed DAF(-/-)CD59(-/-) mice with mice deficient in various complement components or receptors including C3, C4, factor B (fB), factor properdin (fP), mannose-binding lectin, C3aR, C5aR, or Ig and assessed renal IRI in the resulting mutant strains. We found that deletion of C3, fB, fP, C3aR, or C5aR significantly ameliorated renal IRI in DAF(-/-)CD59(-/-) mice, whereas deficiency of C4, Ig, or mannose-binding lectin had no effect. Treatment of DAF(-/-)CD59(-/-) mice with an anti-C5 mAb reduced renal IRI to a greater degree than did C5aR deficiency. We also generated and tested a function-blocking anti-mouse fP mAb and showed it to ameliorate renal IRI when given to DAF(-/-)CD59(-/-) mice 24 h before, but not 4 or 8 h after, ischemia/reperfusion. These results suggest that complement is activated via the alternative pathway during the early phase of reperfusion, and both anaphylatoxin-mediated inflammation and the membrane attack complex contribute to tissue injury. Further, they demonstrate a critical role for properdin and support its therapeutic targeting in renal IRI.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23427256      PMCID: PMC3608836          DOI: 10.4049/jimmunol.1202275

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

Review 1.  Complement and renal ischemia-reperfusion injury.

Authors:  J V Bonventre
Journal:  Am J Kidney Dis       Date:  2001-08       Impact factor: 8.860

2.  B cell deficiency confers protection from renal ischemia reperfusion injury.

Authors:  Melissa J Burne-Taney; Dolores B Ascon; Frank Daniels; Lorraine Racusen; William Baldwin; Hamid Rabb
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

3.  Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury.

Authors:  Ming Zhang; William G Austen; Isaac Chiu; Elisabeth M Alicot; Rachel Hung; Minghe Ma; Nicola Verna; Min Xu; Herbert B Hechtman; Francis D Moore; Michael C Carroll
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-03       Impact factor: 11.205

4.  A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats.

Authors:  Thiruma V Arumugam; Ian A Shiels; Anna J Strachan; Giovani Abbenante; David P Fairlie; Stephen M Taylor
Journal:  Kidney Int       Date:  2003-01       Impact factor: 10.612

5.  Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes.

Authors:  Pierce Park; Mark Haas; Patrick N Cunningham; Lihua Bao; Jessy J Alexander; Richard J Quigg
Journal:  Am J Physiol Renal Physiol       Date:  2002-02

6.  Predominant role for C5b-9 in renal ischemia/reperfusion injury.

Authors:  W Zhou; C A Farrar; K Abe; J R Pratt; J E Marsh; Y Wang; G L Stahl; S H Sacks
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

7.  Complement factor C5a mediates renal ischemia-reperfusion injury independent from neutrophils.

Authors:  Bart de Vries; Jörg Köhl; Wouter K G Leclercq; Tim G A M Wolfs; Annemarie A J H M van Bijnen; Peter Heeringa; Wim A Buurman
Journal:  J Immunol       Date:  2003-04-01       Impact factor: 5.422

8.  Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice.

Authors:  Joshua M Thurman; Danica Ljubanovic; Charles L Edelstein; Gary S Gilkeson; V Michael Holers
Journal:  J Immunol       Date:  2003-02-01       Impact factor: 5.422

9.  Critical protection from renal ischemia reperfusion injury by CD55 and CD59.

Authors:  Koei Yamada; Takashi Miwa; Jianuo Liu; Masaomi Nangaku; Wen-Chao Song
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

10.  Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis.

Authors:  Allison M Lesher; Lin Zhou; Yuko Kimura; Sayaka Sato; Damodar Gullipalli; Andrew P Herbert; Paul N Barlow; Hannes U Eberhardt; Christina Skerka; Peter F Zipfel; Takayuki Hamano; Takashi Miwa; Kenneth S Tung; Wen-Chao Song
Journal:  J Am Soc Nephrol       Date:  2012-11-30       Impact factor: 10.121

View more
  36 in total

1.  Anti-mouse properdin TSR 5/6 monoclonal antibodies block complement alternative pathway-dependent pathogenesis.

Authors:  Paula Bertram; Antonina M Akk; Hui-fang Zhou; Lynne M Mitchell; Christine T N Pham; Dennis E Hourcade
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-02

2.  Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia.

Authors:  Yoshiyasu Ueda; Takashi Miwa; Damodar Gullipalli; Sayaka Sato; Daisuke Ito; Hangsoo Kim; Matthew Palmer; Wen-Chao Song
Journal:  J Am Soc Nephrol       Date:  2018-06-01       Impact factor: 10.121

3.  Complement C5 Inhibition Reduces T Cell-Mediated Allograft Vasculopathy Caused by Both Alloantibody and Ischemia Reperfusion Injury in Humanized Mice.

Authors:  L Qin; G Li; N Kirkiles-Smith; P Clark; C Fang; Y Wang; Z-X Yu; D Devore; G Tellides; J S Pober; D Jane-Wit
Journal:  Am J Transplant       Date:  2016-06-14       Impact factor: 8.086

4.  Functional and structural insight into properdin control of complement alternative pathway amplification.

Authors:  Dennis V Pedersen; Lubka Roumenina; Rasmus K Jensen; Trine Af Gadeberg; Chiara Marinozzi; Capucine Picard; Tania Rybkine; Steffen Thiel; Uffe Bs Sørensen; Cordula Stover; Veronique Fremeaux-Bacchi; Gregers R Andersen
Journal:  EMBO J       Date:  2017-03-06       Impact factor: 11.598

5.  Exploration of Serum Marker Proteins in Mice Induced by Babesia microti Infection Using a Quantitative Proteomic Approach.

Authors:  Xiaoshuang Wang; Shuguang Ren; Xiaohong Yang; Abolfazl Masoudi; Xiaomin Xue; Mengxue Li; Hongxia Li; Xiaojing Zhang; Hui Wang; Jingze Liu
Journal:  Protein J       Date:  2021-01-02       Impact factor: 2.371

6.  C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.

Authors:  Allison Lesher Williams; Damodar Gullipalli; Yoshiyasu Ueda; Sayaka Sato; Lin Zhou; Takashi Miwa; Kenneth S Tung; Wen-Chao Song
Journal:  Kidney Int       Date:  2017-01-27       Impact factor: 10.612

Review 7.  Therapeutic control of complement activation at the level of the central component C3.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Immunobiology       Date:  2015-06-10       Impact factor: 3.144

8.  Complement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration.

Authors:  Chunmei Piao; Lun Cai; Shulan Qiu; Lixin Jia; Wenchao Song; Jie Du
Journal:  J Biol Chem       Date:  2015-03-04       Impact factor: 5.157

9.  Combination of factor H mutation and properdin deficiency causes severe C3 glomerulonephritis.

Authors:  Allison M Lesher; Lin Zhou; Yuko Kimura; Sayaka Sato; Damodar Gullipalli; Andrew P Herbert; Paul N Barlow; Hannes U Eberhardt; Christina Skerka; Peter F Zipfel; Takayuki Hamano; Takashi Miwa; Kenneth S Tung; Wen-Chao Song
Journal:  J Am Soc Nephrol       Date:  2012-11-30       Impact factor: 10.121

Review 10.  Properdin in complement activation and tissue injury.

Authors:  Allison M Lesher; Bo Nilsson; Wen-Chao Song
Journal:  Mol Immunol       Date:  2013-06-29       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.